Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Feb 29, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Two Studies Evaluate 2nd Line Pancreatic Cancer Treatments Following Abraxane

 

Two analyses presented during the American Society of Clinical Oncology’s 2016 Gastrointestinal Cancers Symposium evaluated the results of second-line treatment following treatment with a combination of Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound) and gemcitabine in first-line metastatic pancreatic cancer patients.

A post-hoc analysis of the phase III study MPACT, which evaluated Abraxane and gemcitabine compared with gemcitabine alone in first-line metastatic pancreatic cancer patients, evaluated the outcomes of patients who received a second-line treatment during an observational extension of the study.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter